Gilead Sciences Inc. (GILD)

76.35
0.29 0.38
NASDAQ : Health Technology
Prev Close 76.06
Open 76.31
Day Low/High 75.65 / 77.09
52 Wk Low/High 60.89 / 85.97
Volume 6.36M
Avg Volume 16.87M
Exchange NASDAQ
Shares Outstanding 1.25B
Market Cap 96.51B
EPS 4.20
P/E Ratio 19.73
Div & Yield 2.72 (3.45%)
Cramer: Step Away and Get Your Clients Better Prices

Cramer: Step Away and Get Your Clients Better Prices

You mean to tell me if the buyers walked away for 10 minutes they couldn't get these stocks lower?

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Gilead Upgraded to Buy at Jefferies

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

Key Feature in Marketks

The key feature within the markets is the renewed and continued strength in pharma and biotech which started last week. Allergan , Celgene and Gilead Sciences  are upside features. I am not involved and I would not chase big Pharma or biotech.

Erytech Pharma Plummets on Phase 2 Data -- Biotech Movers

Erytech Pharma Plummets on Phase 2 Data -- Biotech Movers

France-based firm said its Phase 2 study of eryaspase (Graspa) in acute myeloid leukemia did not achieve its primary endpoint of overall survival.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

Mid-Afternoon Observations

Some mid afternoon observations:   * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Here's What's Up This A.M.

The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower.   Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside.   Co...

Big-Cap Biotechs Are Dragging

Biotech is conspicuously weak, with weakness in Allergan , Celgene and Gilead Sciences .   I suspect we could see tax selling in December, but it's still early.   Speculative biotech is not much better.   I am avoiding the sector for now.

Gilead Has Trouble Written All Over It

Gilead Has Trouble Written All Over It

Getting back into an uptrend will be a challenge for GILD.

Allergan's Drop Provides 10 Important Investing Lessons

Allergan's Drop Provides 10 Important Investing Lessons

On Thursday, I waved the white flag exited my AGN position.

Allergan's Ten Important Lessons

To me, there are a number of important lessons in Allergan's  $11 drop today:   There is no substitute for objective and hard-hitting security analysis. A variant view can be special and deliver alpha -- it can contribute importantly to avoiding los...

Potholes in the Market

Despite stocks near their all-time records, there are more potholes (this week) than observed on Second Avenue in the Upper East Side in New York City.  Today's potholes:  * Optical (Oclaro guidedown) * FANG (reaction to earnings) * Retail (again) *...

This Allergan Bull Reluctantly Waves the White Flag and Exits the Stock

This Allergan Bull Reluctantly Waves the White Flag and Exits the Stock

Looking ahead, Allergan may be more vulnerable than suggested by management or believed by analysts.

3 Small-Caps on My Growth Stock Radar

3 Small-Caps on My Growth Stock Radar

LGI Homes, ANI Pharmaceuticals and Sonus Networks are worth considering.

3 Biotech Stalwarts Just Can't Bio a Break

3 Biotech Stalwarts Just Can't Bio a Break

The stocks of Amgen, Celgene and Gilead Sciences all took hits after posting quarterly results.

Remember That Bumps in the Road Are Normal: Market Recon

Remember That Bumps in the Road Are Normal: Market Recon

The forces that artificially impacted the marketplace return to normal; so will the marketplace itself.

Gilead Sciences Poised to Make a Push Toward $100?

Gilead Sciences Poised to Make a Push Toward $100?

We have a new price target as GILD reacts to the FDA approving its cancer drug.

Amazon's HQ2, Cancer Therapy Approved: Thursday's Top Stories

Amazon's HQ2, Cancer Therapy Approved: Thursday's Top Stories

Today's Top Stories: Amazon's deadline to submit a proposal to build a new headquarters is today, Gilead shares are jumping as a result of the FDA's approval of a cancer treatment, today marks the 30th anniversary of Black Monday.

Dow Powers to New Record, Nears 23,000

Dow Powers to New Record, Nears 23,000

The Dow, the Nasdaq and the S&P 500 all reached new record highs even though drug stocks were under pressure following comments by President Trump.

My Takeaways and Observations

"While options can give market participants the protection they are intended to provide, they can also increase the degree of a counter move, once it gets going, as those who wrote the protection scramble to unwind their own exposure." -- Kass Diary...

Why Is Flexion Falling, and Other Questions

Why Is Flexion Falling, and Other Questions

The first part of Flexion's decline can be attributed to some profit taking.

My Takeaways and Observations (Early Afternoon Edition)

"Why make trillions when we can make billions?" -- Dr. Evil I started the day with a multi-part series, "Sell FANG."  Here, here and here.  A Bull Market in Complacency -- why volatility is low and corrections are non existent.   Auction Action.   N...

Some Weak Names Today

An old trading dictim is that you might consider selling or shorting stocks that are in the red when the market is broadly in the green (and vice versa).   Some conspicuous stocks that are weak today include Comcast , Gilead , Sprint , and Lilly .

Upgrade Confirms Gilead's Price Strength

Upgrade Confirms Gilead's Price Strength

But is it too late?

Getting Bullish on Gilead

Getting Bullish on Gilead

I'm setting up a risk reversal to either buy the stock lower or participate in the upside.